We have envisaged for quite a while that Kabi will have to leave its IV drug Shangri La. This has now happened. Should one worry about this? The Q3 figures show that other segments could cushion the effects of greater competition in this segment to a certain extent. What looks more interesting is what is going on in the clinic business where some clouds are gathering over the sun (Helios). Or is it just a penumbral solar eclipse?
29 Oct 2019
Helios' eclipse?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Helios' eclipse?
Fresenius SE & Co. KGaA (FRE:WBO) | 0 0 0.5% | Mkt Cap: 35,173m
- Published:
29 Oct 2019 -
Author:
Martin Schnee -
Pages:
3
We have envisaged for quite a while that Kabi will have to leave its IV drug Shangri La. This has now happened. Should one worry about this? The Q3 figures show that other segments could cushion the effects of greater competition in this segment to a certain extent. What looks more interesting is what is going on in the clinic business where some clouds are gathering over the sun (Helios). Or is it just a penumbral solar eclipse?